ArticleProtein science : a publication of the Protein Society2026
The structural heterogeneity of AKT autoinhibition.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Kinase cascades: emerging design principles and guidelines.RSC chemical biology · 2026Review
- How Functional Variants Reconfigure the Rac2 Conformational Landscape.The journal of physical chemistry. B · 2026Article
- The structural basis of RanGAP1 regulation and catalysis in nuclear transport.bioRxiv : the preprint server for biology · 2026Article
- How Functional Variants Reconfigure the Rac2 Conformational Landscape.bioRxiv : the preprint server for biology · 2026Article
- The structural heterogeneity of AKT autoinhibition.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
AKT is key to controlling cell growth through the PI3K/AKT/mTOR pathway. In the cytosol, in the absence of stimulus, AKT is autoinhibited to prevent uncontrolled activation. Increased AKT activity contributes to tumor growth by phosphorylating numerous downstream targets. Relieving the autoinhibition is a prerequisite for full activation, which occurs through C-terminal tail phosphorylation by mTOR, followed by activation loop phosphorylation by PDK1. However, the atomic-level mechanisms by which AKT autoinhibition persists in the cytosol and the phosphorylation (posttranslational modifications) allosterically shift AKT to its open conformation, which may serve as drug targets, remain unclear. Here, we performed explicit molecular dynamics simulations to explore the conformational ensembles of AKT in these different states. Our unbiased results show how the variable loops of the PH domain contribute to the PH-mediated AKT autoinhibition. Autoinhibited states are commonly only marginally stable, populating function-related shallow metastable wells with relatively similar energies and low kinetic barriers, making them receptive to regulation. The conformational heterogeneity of AKT's autoinhibitory interface is susceptible to regulation, including by phosphorylation, but also by activating mutations and allosteric inhibitors. As to activation by phosphorylation, allosteric communication between the phosphorylated C-terminal tail and the PH domain of AKT promotes the release of the PH domain from the kinase domain, independent of PIP
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.